Literature DB >> 34427738

Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin.

Kouichi Ohya1, Shuhei Okuyama1, Shin-Ya Ogata2, Kunihiko Maeda3, Kyohei Yamada4, Kouichi Ohshima4, Katsushi Tajima5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34427738     DOI： 10.1007/s00277-021-04633-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  7 in total

Review 1.  A suggested immunohistochemical algorithm for the classification of T-cell lymphomas involving lymph nodes.

Authors:  Francisco Vega; L Jeffrey Medeiros
Journal:  Hum Pathol       Date:  2020-05-29       Impact factor: 3.466

2.  Three coexisting lymphomas in a single patient: composite lymphoma derived from a common germinal center B-cell precursor and unrelated discordant lymphoma.

Authors:  Atsujiro Nishioka; Hiroshi Ureshino; Toshihiko Ando; Haruna Kizuka; Kana Kusaba; Haruhiko Sano; Hidekazu Itamura; Yasushi Kubota; Kensuke Kojima; Koichi Ohshima; Shinya Kimura
Journal:  Int J Hematol       Date:  2017-11-25       Impact factor: 2.490

Review 3.  Pathogenesis, diagnosis, and treatment of composite lymphomas.

Authors:  Ralf Küppers; Ulrich Dührsen; Martin-Leo Hansmann
Journal:  Lancet Oncol       Date:  2014-09       Impact factor: 41.316

Review 4.  [Pharmacology of isoxazole and pyrazole derivatives].

Authors:  J Vetulani
Journal:  Postepy Hig Med Dosw       Date:  1968 Mar-Apr       Impact factor: 0.270

5.  Application of a 5 Marker Panel to the Routine Diagnosis of Peripheral T-Cell Lymphoma With T-Follicular Helper Phenotype.

Authors:  Basma M Basha; Sandra C Bryant; Karen L Rech; Andrew L Feldman; Julie A Vrana; Min Shi; Katelyn A Reed; Rebecca L King
Journal:  Am J Surg Pathol       Date:  2019-09       Impact factor: 6.394

6.  Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

Authors:  Eric D Jacobsen; Jeff P Sharman; Yasuhiro Oki; Ranjana H Advani; Jane N Winter; Celeste M Bello; Gary Spitzer; Maria Corinna Palanca-Wessels; Dana A Kennedy; Pamela Levine; Jing Yang; Nancy L Bartlett
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

7.  Clinicopathological analysis of a composite lymphoma containing both T- and B-cell lymphomas.

Authors:  Nobuko Suefuji; Daisuke Niino; Fumiko Arakawa; Kennosuke Karube; Yoshizo Kimura; Junichi Kiyasu; Masanori Takeuchi; Hiroaki Miyoshi; Maki Yoshida; Ayako Ichikawa; Yasuo Sugita; Koichi Ohshima
Journal:  Pathol Int       Date:  2012-10       Impact factor: 2.534
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.